Nephrology and Kidney Transplantation Unit, Department of Translational Medicine and Center for Autoimmune and Allergic Diseases (CAAD), University of Piemonte Orientale (UPO), Novara, Italy.
Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Nephron. 2020;144(12):638-643. doi: 10.1159/000511347. Epub 2020 Oct 30.
Acute kidney injury (AKI) is a frequent complication of hospital admission and worsens short- and long-term patients' prognosis. Currently, AKI treatment remains supportive and no therapy has proven significant benefit in clinical trials. Stem cells (SCs) are a promising therapeutic option, but their translation to the clinical setting is limited by the risk of rejection or aberrant differentiation. Numerous studies have shown how SC effects are mediated by paracrine factors such as extracellular vesicles (EVs). In this review, we describe the preclinical evidence about EV efficacy in acute tubular and glomerular injury and the recently generated clinical data.
急性肾损伤（AKI）是住院患者的常见并发症，会恶化患者的短期和长期预后。目前，AKI 的治疗仍然以支持性治疗为主，临床试验中没有哪种疗法被证明有显著获益。干细胞（SCs）是一种很有前途的治疗选择，但由于存在排斥或异常分化的风险，其向临床应用的转化受到限制。许多研究表明，SCs 通过细胞外囊泡（EVs）等旁分泌因子发挥作用。在这篇综述中，我们描述了 EV 在急性肾小管和肾小球损伤中的临床前疗效证据，以及最近产生的临床数据。
